Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Niranjan J Sathianathen; Philipp Dahm; Sarah Jane Brown; Makinna Oestreich; Shilpa Gupta; Badrinath R Konety; Frank Kunath

doi:10.1002/14651858.CD013245

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Niranjan J Sathianathen
, Philipp Dahm
, Sarah Jane Brown
, Makinna Oestreich
, Shilpa Gupta
, Badrinath R Konety
, Frank Kunath

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of early abiraterone acetate in combination with androgen deprivation therapy for newly diagnosed metastatic hormone-sensitive prostate cancer.

Original language	English (US)
Article number	CD013245
Journal	Cochrane Database of Systematic Reviews
Volume	2019
Issue number	1
DOIs	https://doi.org/10.1002/14651858.CD013245
State	Published - Jan 24 2019

Bibliographical note

Publisher Copyright:
© 2019 The Cochrane Collaboration.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1002/14651858.CD013245

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353243

Find It

Find It at U of M Libraries

Cite this

Sathianathen, N. J., Dahm, P., Brown, S. J., Oestreich, M., Gupta, S., Konety, B. R., & Kunath, F. (2019). Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. Cochrane Database of Systematic Reviews, 2019(1), Article CD013245. https://doi.org/10.1002/14651858.CD013245

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. / Sathianathen, Niranjan J; Dahm, Philipp; Brown, Sarah Jane et al.
In: Cochrane Database of Systematic Reviews, Vol. 2019, No. 1, CD013245, 24.01.2019.

Research output: Contribution to journal › Article › peer-review

@article{545b3f79ff1143b587a83ef0a0641dad,

title = "Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer",

abstract = "This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of early abiraterone acetate in combination with androgen deprivation therapy for newly diagnosed metastatic hormone-sensitive prostate cancer.",

author = "Sathianathen, \{Niranjan J\} and Philipp Dahm and Brown, \{Sarah Jane\} and Makinna Oestreich and Shilpa Gupta and Konety, \{Badrinath R\} and Frank Kunath",

note = "Publisher Copyright: {\textcopyright} 2019 The Cochrane Collaboration.",

year = "2019",

month = jan,

day = "24",

doi = "10.1002/14651858.CD013245",

language = "English (US)",

volume = "2019",

journal = "Cochrane Database of Systematic Reviews",

issn = "1361-6137",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

TY - JOUR

T1 - Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

AU - Sathianathen, Niranjan J

AU - Dahm, Philipp

AU - Brown, Sarah Jane

AU - Oestreich, Makinna

AU - Gupta, Shilpa

AU - Konety, Badrinath R

AU - Kunath, Frank

PY - 2019/1/24

Y1 - 2019/1/24

N2 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of early abiraterone acetate in combination with androgen deprivation therapy for newly diagnosed metastatic hormone-sensitive prostate cancer.

AB - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of early abiraterone acetate in combination with androgen deprivation therapy for newly diagnosed metastatic hormone-sensitive prostate cancer.

UR - https://www.scopus.com/pages/publications/85060402305

UR - https://www.scopus.com/pages/publications/85060402305#tab=citedBy

U2 - 10.1002/14651858.CD013245

DO - 10.1002/14651858.CD013245

M3 - Article

AN - SCOPUS:85060402305

SN - 1361-6137

VL - 2019

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 1

M1 - CD013245

ER -

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this